Results 11 to 20 of about 2,313 (149)

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Frontiers in Immunology, 2019
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment.
Starlynn C. Clarke, Biao Ma, Nathan D. Trinklein, Ute Schellenberger, Michael J. Osborn, Laure-Hélène Ouisse, Andrew Boudreau, Laura M. Davison, Katherine E. Harris, Harshad S. Ugamraj, Aarti Balasubramani, Kevin H. Dang, Brett Jorgensen, Heather Anne N. Ogana, Duy T. Pham, Payal P. Pratap, Preethi Sankaran, Ignacio Anegon, Wim C. van Schooten, Marianne Brüggemann, Roland Buelow, Shelley Force Aldred   +21 more
doaj   +3 more sources

Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers [PDF]

Discover Oncology
Bispecific antibodies (BsAbs) and multispecific antibodies (MsAbs) represent a transformative class of immunotherapeutics in oncology. These engineered molecules possess the unique ability to simultaneously target two or more distinct antigens, thereby ...
Mustafa T. Ardah, Waleed K. Abdulsahib, Ihsan Khudhair Jasim, H. Malathi, Pradeepta Sekhar Patro, D. Alex Anand, Gunjan Mukherjee, Aashna Sinha, Shakhrijakhon Aminqulov   +8 more
doaj   +2 more sources

Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Hematologic disorders, including sickle cell disease, anemias, hemoglobinopathies, leukemias, lymphomas, and bleeding disorders, constitute a substantial and growing burden of morbidity and mortality across Africa. Structural health system constraints—limited diagnostic capacity, shortages of trained hematology specialists ...
Obeagu EI.
europepmc   +2 more sources

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer [PDF]

International Journal of Molecular Sciences, 2021
Petros Christopoulos, Christopoulos Petros   +1 more
exaly   +2 more sources

Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization [PDF]

Scientific Reports
Programmed death-ligand 1 (PD-L1) plays a key role in tumor immune evasion by suppressing T cell activity through its interaction with programmed death-1 (PD-1).
Ji Hyun Lee, Su Yeon Cho, Hee Eon Lee, Sukmook Lee   +3 more
doaj   +2 more sources

Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses. [PDF]

J Med Virol
ABSTRACT SARS‐CoV‐2 and MERS‐CoV are highly pathogenic and contagious coronaviruses. Despite intensive vaccination, SARS‐CoV‐2 continues to spread, and no FDA‐approved vaccines exist for MERS‐CoV; thus, more effective and safer vaccine options are needed. The receptor‐binding domain (RBD) of coronaviruses is a primary target of neutralizing antibodies (
Helal A, Aljehani ND, Ghazwani A, Alsulaiman RM, Alyami F, Abdulaal WH, Alsharef A, Alghanmi M, Zawawi A, Azhari AA, Almehmadi A, Balula J, Altorki T, Alhabbab RY, Khan MY, Alluhaybi K, Alnami A, Neamatallah T, Abujamel TS, Alfaleh MA, Hashem AM.   +20 more
europepmc   +2 more sources

scFv-based biologics in diabetes: from therapeutic potential to clinical prospects [PDF]

Frontiers in Immunology
The global epidemic of diabetes mellitus the limitations of current therapies-including waning efficacy, adverse effects, and inability to modify disease progression-have accelerated the shift from conventional pharmacotherapy toward biologic agents ...
Shikun Ge, Luoxuan Wang, Yichen Huang, Huaizu Guo, Huaizu Guo, Huaizu Guo, Fuyao Wei, Pan Li, Siyuan Li, Qian Liu, Jin Xu, Jin Xu, Yilei Xiao, Alberto Carlos Piress Dias, Lusha Ji   +14 more
doaj   +2 more sources

From discovery to the clinic: structural insights, engineering options, clinical, and ‘next wave’ applications of camelid-derived single-domain antibodies [PDF]

mAbs
Camelid-derived single domain antibodies (sdAbs), referred to as VHHs (variable domains of the heavy chain of a heavy chain-only antibodies), recently emerged as promising building blocks for the construction of therapeutic molecules. As of October 2025,
Andreas Evers, Enrico Guarnera, Lukas Pekar, Stefan Zielonka   +3 more
doaj   +2 more sources

Engineered mRNA and the Rise of Next-Generation Antibodies

Antibodies, 2021
Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs.
Laura Sanz, Luis Álvarez-Vallina
doaj   +1 more source

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Frontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei, Yueyao Yang, Gang Wang, Ming Liu   +3 more
doaj   +1 more source